The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, R.
Right arrow Articles by Shi, F.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, R.
Right arrow Articles by Shi, F.-D.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Autoimmune Diseases
The Journal of Immunology, 2006, 176: 5247-5254.
Copyright © 2006 by The American Association of Immunologists

Autoreactive T Cells Mediate NK Cell Degeneration in Autoimmune Disease1

Ruolan Liu*, Luc Van Kaer{dagger}, Antonio La Cava{ddagger}, Mary Price*, Denise I. Campagnolo*, Mary Collins§, Deborah A. Young§, Timothy L. Vollmer* and Fu-Dong Shi2,*

* Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ 85013; {dagger} Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232; {ddagger} David Geffen School of Medicine, University of California, Los Angeles, CA 90095; and § Wyeth Research, Cambridge, MA 02140


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Emerging evidence indicates that NK cells play an important and complex role in autoimmune disease. Humans with autoimmune diseases often have reduced NK cell numbers and compromised NK cell functions. Mechanisms underlying this NK cell degeneration and its biological significance are not known. In this study we show that, in an experimental model of human autoimmune myasthenia gravis induced by a self-Ag, the acetylcholine receptor, NK cells undergo proliferation during the initiation of autoimmunity, followed by significant degeneration associated with the establishment of the autoreactive T cell response. We show that NK cell degeneration was mediated by IL-21 derived from autoreactive CD4+ T cells, and that acetylcholine receptor-immunized IL-21R-deficient mice, with competent NK cells, developed exacerbated autoimmunity. Thus, NK cell degeneration may serve as a means evolved by the immune system to control excessive autoimmunity.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Natural killer cells are large granular lymphocytes of the innate immune system and respond rapidly to a variety of insults via cytokine secretion and cytolytic activity ( 1, 2, 3, 4). Recently, there has been growing insight into the biological function of NK cells, particularly with regard to their role in the regulation of autoimmunity in animal models and in humans ( 5, 6, 7). Some studies suggest that NK cells prevent or curb autoimmune responses ( 8, 9, 10, 11). Other results indicate that NK cells have a permissive role in autoimmunity, perhaps due to their ability to provide an early source of cytokines and to activate APCs leading to the development of pathogenic Th1 responses ( 12, 13, 14, 15, 16). Clearly, these studies imply that NK cells can regulate inflammation and loss of self-tolerance at multiple steps and, therefore, suggest that NK cells play distinct roles during different forms and at different stages of autoimmunity.

Although factors that account for the apparently opposing effects of NK cells in autoimmune disease remain to be identified, one finding emerges consistently: NK cell numbers and functions decline during the progression of most autoimmune diseases of humans ( 17, 18, 19). Mechanisms underlying NK cell degeneration in autoimmune disease remain elusive. Environmental triggering coupled with genetic susceptibility is necessary to precipitate overt autoimmune disease. Although infections are frequently associated with relapses of autoimmune disease ( 20), they may not be required to maintain autoimmunity, once initiated. Additionally, NK cells in environments of ongoing autoimmunity may be confronted with excess quantities of cytokines derived from autoreactive T and B cells. The temporal concordance of decreased NK cell responses with the emergence of Ag-specific T cells makes it likely that T cells and T cell-derived factors influence the fate of NK cells. Therefore, we hypothesized that 1) NK cell degeneration stems from a lack of sustained NK cell stimuli during the progression of autoimmune disease; or alternatively, 2) NK cell degeneration is mediated by autoreactive T and/or B cells.

In this study, we demonstrate that NK cell degeneration in experimental autoimmune myasthenia gravis (EAMG) does not result from a lack of sustained stimuli but is, instead, mediated by IL-21 derived from autoreactive CD4+ T cells. Acetylcholine receptor (AChR)-immunized IL-21R-deficient mice, with competent NK cells, developed exacerbated autoimmunity. Our results provide a mechanistic explanation for the long-standing puzzle of NK cell degeneration during the progression of autoimmune diseases and suggest that NK cell degeneration significantly influences the course of autoimmunity.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

C57BL/6 (B6) mice were purchased from Charles River Laboratories or The Jackson Laboratory. RAG1–/– ( 21), B cell-deficient µMt, CD4–/–, CD8–/–, and IL-12–/– mice were purchased from The Jackson Laboratory. IL-18–/– mice ( 22) were provided by Drs. K. Takeda and S. Akira (Japan Science and Technology Agency, Osaka, Japan). IL-15–/– mice ( 23) were provided by Dr. J. J. Peschon (Immunex; Seattle, WA). IL-21R–/– mice ( 24) and CD1d–/– mice ( 25) have been described. All mutant mice were backcrossed 10x to a B6 background.

Induction of EAMG

AChR was purified from the electric organs of Torpedo californica (Pacific Biomarine) by affinity chromatography on a {alpha}-cobrotoxin-agarose resin (Sigma-Aldrich) ( 26). An inoculum of 20 µg of AChR in CFA in a total volume of 100 µl was used to immunize mice s.c. along the shoulders and back. Mice were boosted twice at days 30 and 60 with 20 µg of AChR in CFA or IFA s.c. at four sites on the shoulders and thighs. Clinical manifestations of EAMG were graded between 0 and 3 with standard criteria ( 14). Cumulative disease scores were calculated by adding disease scores weekly from the onset to termination of the experiment.

NK cell isolation

NK cells (NK1.1+CD3–) from pooled splenocytes were enriched with anti-mouse CD49b/pan-NK cell marker (BD Biosciences) or with magnetic beads for CD5 (Miltenyi Biotech). After removal of CD5+ cells, NK cells were sorted from the remaining cells by FACSAria or FACSStar using Diva software (BD Biosciences) ( 9, 10). Purity of NK cells obtained by this approach reached 98%.

NK: T cell coculture

AChR-reactive CD4+ T cells were selected using a split-well assay ( 27). A total of 1–3 x 105 NK cells and AChR-reactive CD4+ T cells/well were cultured together in 48-well plates for 18 h. In some experiments, NK cells and T cells were cultured with a permeable membrane (Transwell) of 6.5-mm diameter and 5-µm pore size (Costar).

NK cell depletion

Mice were given injections i.p. with 250 µg of anti-NK1.1 mAb (PK136 clone) for initial depletion and 100 µg of anti-NK1.1 mAb every 5 days to maintain depletion ( 14).

FACS analysis

Purified cells were stained with the following Abs to mouse Ags: NK1.1, CD3, CD4, and annexin-V (all obtained from BD Biosciences). The cell surface receptor for IL-21 was detected with the use of biotinylated IL-21 (R&D Systems) as described previously ( 28). All samples were analyzed on a FACSAria or FACSCalibur using Diva or CellQuest software (BD Biosciences).

NK cell cytotoxicity assay

NK cell-mediated cytotoxicity was assayed using a standard 51Cr release assay ( 14).

Cytokine ELISA and ELISPOT

Levels of IL-21 in culture supernatants of AChR-reactive T cells during EAMG were quantified by ELISA (mouse rIL-21 and goat anti-IL-21; all obtained from Capralogics). The IFN-{gamma} ELISPOT assay was described previously ( 14).

Lymphocyte labeling with CFSE

Spleen cells were incubated with CFSE at a concentration of 0.5 µM at 37°C for 30 min. Cells were washed and seeded in plates at a concentration of 4 x 105 cells/well. Cells were incubated with or without LPS (1 µg/ml). After 72 h of incubation, the cells were washed, and dilution of CFSE among NK1.1+CD3– cells was analyzed by FACS.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
NK cell degeneration during the progression of autoimmunity

To understand the mechanism underlying the degeneration of NK cells in human autoimmune disease, we adopted EAMG in C57BL/6 (B6) mice, an animal model for the classic T cell-driven, B cell-mediated autoimmune disease MG ( 14). To produce the muscular weakness characteristic of MG in B6 mice, repeated immunization with AChR in CFA (or IFA) is required ( 29). Most mice develop clinical overt muscle weakness after the second immunization, and disease becomes progressive in most animals. The advantage of this model is that the target autoantigen AChR is well defined ( 26) and that the course of EAMG mirrors both the initiation and progression phases of the human disease. The inception of MG and other autoimmune diseases is virtually impossible to monitor in most humans, because they represent clinically silent events occurring many years before clinical presentation of the disease in most patients. Additionally, multiple immunizations serve as a surrogate for environmental triggering in humans and offer sustained NK cell stimuli.

We began our investigation by immune-phenotyping and functional characterization of NK cells during the course of EAMG. In mice immunized with AChR/CFA, splenic NK cells appeared to undergo rapid proliferation from day 1 to 3 postimmunization (p.i.), as evidenced by dilution of CFSE on gated NK cells (Fig. 1a), followed by a numerical decline after day 7 p.i. By day 75 p.i., the percentage and absolute number of NK cells (NK1.1+CD3–) was approximately one-fourth of that in the induction phase of EAMG (Fig. 1, b and d). The dynamic changes in the NK cell compartment during the initiation of EAMG appeared to be the result of NK cell proliferation in situ rather than recruitment, because modest NK cell expansion was also observed in lymph nodes, peripheral blood, and thymus (data not shown). In contrast, there was a moderate increase in the percentage of NK cell in mice injected with CFA at the same frequency, which was maintained throughout the 100-day observation period (Fig. 1, b and c). NK cells from mice treated with AChR/CFA rapidly acquired the ability to lyse YAC-1 target cells (Fig. 1e) and to spontaneously produce IFN-{gamma} (Fig. 1f) at days 3 and 7 p.i. However, from day 15 p.i., NK cell activity started to decline. This deficit in NK cell function was also observed when purified NK cells were activated with LPS (1 µg/ml) (numbers of IFN-{gamma} spot-forming cells in EAMG mice were 47 ± 11 vs 13 ± 4 on day 3 and 75 p.i.). In contrast, mice immunized with CFA alone maintained NK cell functions at a magnitude similar to that preceding their initial priming (Fig. 1, e and f).


Figure 1
View larger version (44K):
[in this window]
[in a new window]
  		FIGURE 1. NK cell degeneration during the progression of autoimmunity. Mice were immunized with AChR/CFA at 3 monthly intervals to induce EAMG. Control mice were immunized with CFA alone at the same frequency (a). Representative plots from three separate experiments (n = 4 mice/group) show the CFSE dilution of gated NK1.1+CD3– cells from splenocytes purified from mice at day 3 after immunization with AChR/CFA. Numbers (b) and percentages (c and d) of NK cells among splenocytes of B6 mice immunized with CFA alone (c) (n = 12 for each time point) or B6 mice immunized with AChR in CFA (d) (n = 6 for each time point) at different time points p.i. e, NK cell-mediated cytotoxicity of splenocytes from naive B6 mice (n = 12), B6 mice immunized with CFA alone (n = 12), or B6 mice immunized with AChR in CFA (n = 4) at days 1, 3, 7, 15, 35, and 75 p.i. Spleen cells were incubated with 51Cr-labeled YAC-1 target cells at an E:T ratio of 100:1. After 4 h of culture, supernatants were counted for 51Cr release in a gamma counter. f, Mean numbers (±SD) of IFN-{gamma} spot-forming colonies of NK cells measured by ELISPOT assay. NK cells from spleen cells of mice indicated in e were enriched and sorted by flow cytometry and cultured for 48 h without Ag stimulation. g, T cell proliferation in response to AChR and {alpha}146–162 peptide (data not shown) was measured by using [3H] incorporation assay for the groups of mice indicated in a. h, Mean numbers of anti-AChR Ab-producing B cells from groups of mice indicated in a were measured by ELISPOT assay. Data shown represent one of three experiments. Similar results were seen in draining lymph nodes (data not shown). Statistical comparisons were performed between AChR/CFA and CFA groups, or between time points within a group. *, p < 0.05; **, p < 0.01.

 
We also examined the kinetics of T cell and autoantibody responses to AChR and its dominant epitope {alpha}146–162 during the course of EAMG. Vigorous T cell proliferation and anti-AChR-producing B cells in response to AChR and {alpha}146–162 emerged around day 6 and 8 p.i., respectively (Fig. 1, g and h, and data not shown), just before the decline in NK cell functions. We observed a similar pattern of NK cell degeneration during progression of the autoimmune response to myelin Ags, including myelin basic protein and myelin oligodendrocyte glycoprotein, whereas the number and functions of NK cells were maintained in mice immunized with CFA and OVA (F.-U. Shi, unpublished observation). These results suggest that 1) NK cells undergo significant degeneration during the transition from EAMG initiation to disease progression; 2) the observed decline in NK cell functions is not caused by the lack of continuous stimuli; and 3) this transition in NK cell function is associated with the emergence of autoreactive T and B cell responses.

Maintenance of NK cell function in mice devoid of CD4+ T cells

The data so far suggest that the interaction of NK cells and autoreactive T and B cells at different stages of autoimmune disease might be very different in nature. RAG1–/– mice have intact cellular components of innate immunity but do not posses T and B cells ( 21). Immunization of RAG1–/– mice with AChR/CFA activates the innate immune system without mounting autoreactive T and B cell responses. Therefore, this strain provides an opportunity to determine whether NK cells become degenerative in the absence of autoreactive T and B cells. Immunization of RAG1–/– mice with AChR and CFA resulted in increased numbers and percentages of NK cells, as well as numbers of IFN-{gamma}-producing cells, as compared with similarly immunized wild-type mice (due to lack of a T and B cell compartment). These levels remained constant from day 1 to 61, and were comparable to levels in CFA-injected RAG1–/– mice (Table I, group 1 and 2). In contrast, the functional characterization of NK cells in µMt mice (deficient in B cells) revealed a decline in NK cell function similar to that in wild-type mice (p < 0.05 for comparison of numbers of NK cells and numbers of IFN-{gamma} spot-forming cells at day 1 and 61 p.i.; Table I, group 3 and 4). Similar results were obtained in AChR/CFA-primed NKT cell-deficient CD1d1 knockout mice (group 9 and 10). These results suggest that the degeneration of NK cells is mediated by T cells and rule out significant contributions of B cells and NKT cells.


View this table:
[in this window]
[in a new window]
  		Table I. Preservation of NK cell functions in mice devoid of CD4+ T cellsa

 
Having determined that NK cell functions are preserved in mice devoid of T cells, we asked whether CD4+ or CD8+ T cells mediate NK cell degeneration in EAMG. For this purpose, we examined NK cell prevalence and functions in AChR/CFA-primed mice with disrupted genes encoding for CD4 or CD8{alpha}. Compared with wild-type mice, AChR/CFA-primed CD8–/– mice had fewer NK cells, reduced capacity to kill YAC-1 targets, and decreased production of IFN-{gamma} (Table I, group 7 and 8). Remarkably, neither the prevalence of NK cells, nor the killing of YAC-1 targets and production of IFN-{gamma} were significantly altered in the AChR/CFA-primed CD4–/– mice (Table I, group 5 and 6). These data strongly suggest that CD4+ T cells are the primary mediators of NK cell degeneration.

IL-21R+ NK cells are prone to cell death

NK cells in environments of ongoing autoimmunity may be confronted with excess quantities of cytokines derived from autoreactive T cells. The shared common {gamma}-chain-binding cytokines that mediate NK cell expansion and survival include IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 ( 23, 24, 28, 30, 31, 32, 33). IL-21 is the cytokine most likely to confer NK cell degeneration because 1) IL-21 is produced only by CD4+ T cells, but not by CD8+ T cells or other types of lymphocytes; and 2) the effects of IL-21 on NK cells depend on their functional status ( 24, 28). In an attempt to link IL-21 with NK cell degeneration during the course of EAMG, we quantified the levels of IL-21 production by AChR-reactive T cells by ELISA. IL-21 became detectable at ~7 days p.i. and was maintained at a relatively high level during the progression of EAMG (Fig. 2a). Next, we determined whether the IL-21R could mark distinct populations of NK cells for survival or death. Using FACS analysis, we probed the surface characteristics of cell death of NK cells at different stages of EAMG. We found that annexin-V expression was greater on gated IL-21R+ NK cells than on IL-21R– NK cells (6.3 vs 11.9%; p < 0.05) at days 3 to 15 after AChR/CFA immunization (Fig. 2b, top two panels). Annexin-V levels were further increased on IL-21R+ NK cells examined on day 61 p.i. (Fig. 2b, bottom panel). The IL-21R+ NK cells constituted ~22% of total NK cells at day 15 of EAMG (Fig. 2c). Thus, IL-21R+ NK cells are more susceptible to apoptosis than IL-21R– NK cells.


Figure 2
View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 2. IL-21R expression on NK cells mediates cell death. Mice were immunized with AChR/CFA at 3 monthly intervals to induce EAMG. Control mice were immunized with CFA alone at the same frequency (a). Production of IL-21 by AChR-stimulated T cells over the course of EAMG. Four mice at each time point were sacrificed, and splenocytes were cultured in the presence or absence of 10 µg/ml AChR. After 24 h of culture, production of IL-21 was measured by ELISA. b, Expression of annexin-V on gated IL-21R+ or IL-21R– NK cells. Histogram plots show levels of annexin-V expression on gated NK1.1+CD3– splenocytes. c, Percentage of IL-21R+ NK cells in EAMG at day 15 p.i. Data shown represent one of two experiments with n = 4/group. Statistical comparisons were performed between AChR/CFA and CFA groups, or between time points within a group. *, p < 0.05; **, p < 0.01.

 
IL-21 produced by autoreactive CD4+ T cells mediates NK cell degeneration

To determine whether cytokines produced by autoreactive CD4+ T cells are indeed responsible for NK cell degeneration, we performed NKT cell coculture experiments. NK cells cultured with the supernatant of AChR-reactive CD4+ cells, or with CD4+ cells themselves (with or without Transwell), produced less IFN-{gamma} than controls (Fig. 3a), and the number of NK cells was slightly (NS) decreased as compared with controls (data not shown). These results indicated that AChR-reactive CD4+ T cell-derived factors are responsible for functional decay in the coculture.


Figure 3
View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 3. IL-21 mediates NK cell degeneration. Wild-type (control) mice and IL-21R–/– mice were immunized with AChR/CFA at 3 monthly intervals to induce EAMG. We enriched CD4+ T cells from the pooled splenocytes of AChR/CFA-primed mice (day 15 p.i.) and cultured these cells with irradiated autologous splenocytes serving as APC in the presence of AChR (10 µg/ml). AChR-reactive CD4+ clones were selected using a "split-well" assay ( 27 ). NK cells from AChR/CFA-primed mice (day 3 p.i.) were purified and then cultured for 24 h with supernatants from AChR-reactive CD4+ T cell cultures or with AChR-reactive CD4+ T cells themselves. a, NK cells from wild-type or IL-21R–/– spleen cells incubated for 48 h with culture medium (control) or supernatant from AChR-reactive CD4+ T cultures or CD4+ T cell cultures from wild-type mice. Mean numbers (±SD) of IFN-{gamma} spot-forming NK cells were measured by ELISPOT assay. In some experiments, NK cells and CD4+ T cells were cultured in Transwells. After 48-h culture, CD4+ cells were removed from culture by a mAb. b, Percentages of NK cells among splenocytes at days 3 and 75 p.i. from wild-type mice and IL-21R–/– mice were determined by FACS. c, NK cell-mediated cytotoxicity of splenocytes from wild-type mice and IL-21R–/– mice against 51Cr-labeled YAC-1 target cells at an E:T ratio of 100:1. d, Mean numbers (±SD) of IFN-{gamma} spot-forming NK cells were measured by ELISPOT assay. NK cells from mice indicated in b were enriched from the spleen, sorted by flow cytometry, and cultured for 48 h without Ag stimulation. Data shown represent one of two experiments with n = 4/group. Results were similar for cells from draining lymph nodes (data not shown). Statistical comparisons were performed between AChR/CFA and CFA groups, or between time points within a group. *, p < 0.05.

 
Because IL-21R+ NK cells are short lived, we investigated whether IL-21 produced by AChR-reactive CD4+ T cells mediates NK cell degeneration. No blocking Abs to IL-21 are available, which prevented us from addressing this issue in NKT cell coculture experiments. Instead, we reasoned that, if IL-21 indeed mediates NK cell degeneration, IL-21R–/– NK cells would not undergo such degeneration during the progression of EAMG. To assess this possibility, we immunized wild-type and IL-21R–/– mice ( 24) with AChR/CFA. Compared with wild-type mice, IL-21R deficiency had no significant alterations in T cell proliferative responses to AChR and to its dominant epitope {alpha}146–162 (data not shown). Furthermore, NK cell numbers (Fig. 3b), cytotoxicity (Fig. 3c), and IFN-{gamma} production (Fig. 3d) remained unaltered. Thus, we have identified IL-21 as a primary mediator of NK cell degeneration in EAMG.

To determine the contributions of other cytokines that may also influence NK cell survival and function during the progression of autoimmunity to AChR, we examined NK cell prevalence and functions in AChR/CFA-primed IL-12–/–, IL15–/– ( 23), and IL-18–/– ( 22) mice and their corresponding control mice. In agreement with previous studies ( 13), AChR/primed IL-12–/– and IL-18–/– mice displayed various degrees of functional NK cell defects compared with control animals (Table II). However, the functional decline continued in these mice throughout the 90-day observation period (Table II). Furthermore, the numerical decrease in NK cells of AChR/CFA-immunized IL-12–/– and IL-18–/– mice resembled that in wild-type mice (Table II). In a previous report, it was shown that IL-15–/– mice have markedly reduced NK cell numbers ( 23). We found that NK cell numbers could not be rescued by AChR/CFA immunization. Although NK cell numbers did not significantly alter during the 90-day observation period, production of IFN-{gamma} by the remaining NK cells declined (Table II). Therefore, the contribution of IL-12, IL-15, and IL-18 to NK cell degeneration in autoimmune disease, if any, is minimal.


View this table:
[in this window]
[in a new window]
  		Table II. NK cell functions in autoantigen-primed mice devoid of IL-12, IL-15, and IL-18a

 
AChR primed-IL-21R–/– mice develop exacerbated autoimmunity

To understand whether NK cell degeneration is an epiphenomenon that develops secondary to autoreactive T cell activation, or NK cell degeneration can impact the progression of autoimmunity, we immunized control mice and IL-21R–/– mice with AChR/CFA and evaluated the development of EAMG. The median day of onset of muscular weakness of MG in control mice and in IL-21R–/– mice was similar (23 ± 7 vs 21 ± 5). However, IL-21R–/– mice developed more severe muscular weakness with significantly high cumulative disease scores (Table III). In addition, IL-21R–/– mice had increased levels of total anti-AChR IgG and IgG2b (Table III). In agreement with a previous report ( 31), we found that levels of AChR-reactive IgG1 were decreased in IL-21R–/– mice (Table III). These data indicated that there was no global B cell defect in IL-21R–/– mice. It has been demonstrated that IgG2b, rather than IgG1, is myasthenogenic in this model ( 14). With regard to T cell responses, there was a slight increase in AChR-induced T cell proliferation in IL-21R–/– mice (data not shown), and production of AChR-induced IFN-{gamma} was increased in IL-21R–/– (Table III), whereas production of AChR-induced IL-4 was comparable in control and IL-21R–/– mice (data not shown).


View this table:
[in this window]
[in a new window]
  		Table III. NK cells are responsible for the exacerbated autoimmunity in IL-21R–/–

 
NK cells are responsible for the enhanced autoimmunity in IL-21R–/– mice

NK cells in IL-21R–/– mice, which do not undergo degeneration, may sustain autoreactive T cells and contribute to enhanced autoimmunity. To test this possibility, we depleted NK1.1+ cells in AChR-immunized IL-21R–/– mice using anti-NK1.1 mAb. Table III illustrates that NK1.1+ cell depletion before and after immunization reduced the severity of EAMG and the levels of AChR-induced IFN-{gamma}, IgG, and IgG2b. Because anti-NK1.1 mAb depletes both NK and NKT cells, we cross-bred the CD1d–/– mice and IL-21R–/– mice to generate double-mutant mice. AChR-immunized CD1d–/–IL-21R–/– mice developed severe EAMG similar to IL-21R–/– mice, and depletion of NK1.1+ cells in CD1d–/–IL-21R–/– double-mutant mice reversed these effects (data not shown). Therefore, the competent NK cells in IL-21R–/– mice may have a similar role in the initiation and progression of autoimmune responses to AChR. These findings suggest that NK cell degeneration functions to avoid excessive T cell-mediated autoimmunity.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The paradigm that innate immunity plays an instructive role in the acquired immune response is well established ( 3, 6). We now provide evidence that adaptive autoimmune T cell responses can affect the prevalence and function of NK cells, a major cellular player of innate immunity. Our results provide an answer for the long-standing question of how and why NK cells degenerate in the course of human autoimmune disease. Furthermore, the present results also provide a likely mechanistic explanation for earlier findings indicating that depletion of NK cells after T cell activation no longer significantly affects the incidence and severity of experimental autoimmune diseases ( 13, 14).

A time-honored debate is whether NK cell defects are a primary feature of autoimmune disease or secondary either to pathogenesis or therapeutic intervention ( 6, 7, 17). The association between decreased NK cell function and autoimmunity has fueled an attractive hypothesis that autoimmunity results from a lack of suppressive influence of NK cells ( 19). Our results do not support this notion. Instead, NK cells promoted the genesis of autoreactive Th1 cells and disease during the initiation of autoimmunity ( 13, 14). As portrayed in this study, once autoreactive T cells came into play, NK cells were controlled by T cell derived-cytokines that led to a functional deficiency and partial deletion of NK cells. Thus, this NK cell degeneration may signify the transition from innate immune triggering to the emergence of adaptive (autoreactive) T cells. The stage of an autoimmune response therefore determines the nature of NKT cell interactions.

The question arises whether NK cell degeneration is just an epiphenomenon that occurs secondary to autoreactive T cell activation, or whether NK cell degeneration has any impact on the progression of autoimmunity. Our results revealed that IL-21R–/– mice, with competent NK cells, developed exacerbated autoimmunity against AChR. Depletion of NK cells in IL-21R–/– mice abolished these effects. Thus, NK cell degeneration would have a profound impact on progression of autoimmunity. In other words, if autoreactive T cells do not turn off NK cells, as in the case of IL-21R–/– mice, autoimmunity can become excessive.

In pathophysiological circumstances, NK cells and T cells can be colocalized in several peripheral lymphoid compartments including lymph nodes ( 34, 35). This anatomical proximity enhances the likelihood of direct/indirect interactions between NK cells and T cells. Accumulating evidence suggests that the cross-talk between NK cells and T cells can be mediated by APCs (e.g., dendritic cells) or via costimulatory molecules and cytokines. Dendritic cells may carry NK cell-derived helper signals to direct differentiation of Th1 cells ( 36, 37). OX40-OX40 ligand ( 38) and 2B4-CD48 (39) interactions can also mediate activation and proliferation of Ag-specific T cells induced by NK cells. However, the outcome of NKT cell cross-talk is not unidirectional. For example, in elegant studies by Fehniger et al. ( 34), it was shown that endogenous T cell-derived IL-2, acting through the high-affinity IL-2R, costimulates CD56bright NK cells to secrete IFN-{gamma}.

Although several studies have demonstrated reciprocal activating interactions between NK cells and other lymphocytes, including T cells ( 34, 38, 39), the biological outcomes of NKT cell interactions mediated by different stimuli under varied conditions might be quite diverse. Indeed, our study demonstrates a suppressive outcome of NKT cell cross-talk during the progression of autoimmune responses against AChR. This type of interaction was not mediated by cytokines that affect NK cell development, functional maturation, and survival under steady-state conditions, because NK cell degeneration did not occur in mice lacking IL-12, IL-18, and IL-15 (Table II). Instead, the NK cell degeneration during EAMG was mediated by IL-21-derived from AChR-reactive CD4+ T cells, because IL-21R–/– NK cells were resistant to cell death (Fig. 2b), and IL-21R–/– NK cells were not depleted and did not undergo a functional decline during EAMG (Fig. 3).

The reported effects of IL-21 on lymphocytes appear to be very broad and sometimes paradoxical. IL-21 can promote activation and expansion of T, B, and NK cell populations, and can also induce cell death ( 24, 28, 32, 33). The impact of IL-21 on NK cells appears to be dependent on the functional status of these cells ( 24, 28), and IL-21 has been proposed as the essential controller for transition from innate immunity to adaptive immunity ( 24). We assert that T cells have two types of influence on NK cells. First, under conditions of persistent pathogenic insults and infections, T cells support NK cells to maintain an innate immune defense by providing IL-2. Second, to prevent autoimmunity, T cells curb NK cells to avoid the excessive costimulation they can generate, in a mechanism involving IL-21. Collectively, control of NK cells by autoreactive T cells may serve as a subtle but effective means evolved by the immune system to prevent excessive autoimmunity.


   Acknowledgments
 
We thank Drs. K. Takeda, S. Akira, and J. J. Peschon for providing mutant mice; D. DeNardo and M. Senices for assistance with animal experiments; P. Minick for editorial assistance; and S. Rhodes and the Barrow Neuroimmunology Team for their keen interest and sustained support.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants from the Muscular Dystrophy Association (MDA; to F.-D.S.), Barrow Neurological Foundation (to F.-D.S. and T.L.V.), and National Institutes of Health (to L.V.K., A.L.C., and D.I.C.). R.L. is supported by a Development Grant from MDA. Back

2 Address correspondence and reprint requests to Dr. Fu-Dong Shi, Barrow Neurological Institute, 350 West Thomas Road, Phoenix, AZ 85013-4496. E-mail address: Fu-Dong.Shi{at}chw.edu Back

3 Abbreviations used in this paper: EAMG, experimental autoimmune myasthenia gravis; AChR, acetylcholine receptor; p.i., postimmunization. Back

Received for publication November 10, 2005. Accepted for publication February 15, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Ljunggren, H. G., K. Karre. 1990. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol. Today 11: 237-244. [Medline]
  2. Yokoyama, W. M., S. Kim, A. R. French. 2004. The dynamic life of natural killer cells. Annu. Rev. Immunol. 22: 405-429. [Medline]
  3. Raulet, D. H.. 2004. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat. Immunol. 5: 996-1002. [Medline]
  4. Lanier, L. L.. 2003. Natural killer cell receptor signaling. Curr. Opin. Immunol. 15: 308-314. [Medline]
  5. Zimmer, J., H. Bausinger, H. de la Salle. 2001. Autoimmunity mediated by innate immune effector cells. Trends Immunol. 22: 300-301. [Medline]
  6. Shi, F., H. G. Ljunggren, N. Sarvetnick. 2001. Innate immunity and autoimmunity: from self-protection to self-destruction. Trends Immunol. 22: 97-101. [Medline]
  7. French, A. R., W. M. Yokoyama. 2004. Natural killer cells and autoimmunity. Arthritis Res. Ther. 6: 8-14. [Medline]
  8. Smeltz, R. B., N. A. Wolf, R. H. Swanborg. 1999. Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J. Immunol. 163: 1390-1397. [Abstract/Free Full Text]
  9. Matsumoto, Y., K. Kohyama, Y. Aikawa, T. Shin, Y. Kawazoe, Y. Suzuki, N. Tanuma. 1998. Role of natural killer cells and TCR{gamma}{delta} T cells in acute autoimmune encephalomyelitis. Eur. J. Immunol. 28: 1681-1688. [Medline]
  10. Zhang, B., T. Yamamura, T. Kondo, M. Fujiwara, T. Tabira. 1997. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186: 1677-1687. [Abstract/Free Full Text]
  11. Fort, M. M., M. W. Leach, D. M. Rennick. 1998. A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis. J. Immunol. 161: 3256-3261. [Abstract/Free Full Text]
  12. Maruyama, T., K. Watanabe, I. Takei, A. Kasuga, A. Shimada, T. Yanagawa, T. Kasatani, Y. Suzuki, K. Kataoka, T. Saruta, et al 1991. Anti-asialo GM1 antibody suppression of cyclophosphamide-induced diabetes in NOD mice. Diabetes Res. 17: 37-41. [Medline]
  13. Shi, F. D., K. Takeda, S. Akira, N. Sarvetnick, H. G. Ljunggren. 2000. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-{gamma} by NK cells. J. Immunol. 165: 3099-3104. [Abstract/Free Full Text]
  14. Shi, F. D., H. B. Wang, H. Li, S. Hong, M. Taniguchi, H. Link, L. Van Kaer, H. G. Ljunggren. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1: 245-251. [Medline]
  15. Poirot, L., C. Benoist, D. Mathis. 2004. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc. Natl. Acad. Sci. USA 101: 8102-8107. [Abstract/Free Full Text]
  16. Ogasawara, K., J. A. Hamerman, L. R. Ehrlich, H. Bour-Jordan, P. Santamaria, J. A. Bluestone, L. L. Lanier. 2004. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20: 757-767. [Medline]
  17. Trinchieri, G.. 1989. Biology of natural killer cells. Adv. Immunol. 47: 187-376. [Medline]
  18. Shibatomi, K., H. Ida, S. Yamasaki, T. Nakashima, T. Origuchi, A. Kawakami, K. Migita, Y. Kawabe, M. Tsujihata, P. Anderson, K. Eguchi. 2001. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum. 44: 884-892. [Medline]
  19. Grom, A. A.. 2004. Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?. Arthritis Rheum. 50: 689-698. [Medline]
  20. Buljevac, D., H. Z. Flach, W. C. Hop, D. Hijdra, J. D. Laman, H. F. Savelkoul, F. G. van Der Meche, P. A. van Doorn, R. Q. Hintzen. 2002. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125: 952-960. [Abstract/Free Full Text]
  21. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, V. E. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68: 869-877. [Medline]
  22. Takeda, K., H. Tsutsui, T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Okamura, K. Nakanishi, S. Akira. 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8: 383-390. [Medline]
  23. Kennedy, M. K., M. Glaccum, S. N. Brown, E. A. Butz, J. L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C. R. Willis, et al 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191: 771-780. [Abstract/Free Full Text]
  24. Kasaian, M. T., M. J. Whitters, L. L. Carter, L. D. Lowe, J. M. Jussif, B. Deng, K. A. Johnson, J. S. Witek, M. Senices, R. F. Konz, et al 2002. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16: 559-569. [Medline]
  25. Mendiratta, S. K., W. D. Martin, S. Hong, A. Boesteanu, S. Joyce, L. Van Kaer. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6: 469-477. [Medline]
  26. Vincent, A., D. B. Drachman. 2002. Myasthenia gravis. Adv. Neurol. 88: 159-188. [Medline]
  27. Bielekova, B., M. H. Sung, N. Kadom, R. Simon, H. McFarland, R. Martin. 2004. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J. Immunol. 172: 3893-3904. [Abstract/Free Full Text]
  28. Vollmer, T. L., R. Liu, M. Price, S. Rhodes, A. La Cava, F. D. Shi. 2005. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174: 2696-2701. [Abstract/Free Full Text]
  29. Christadoss, P.. 1989. Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9: 247-278. [Medline]
  30. Gilmour, K. C., H. Fujii, T. Cranston, E. G. Davies, C. Kinnon, H. B. Gaspar. 2001. Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 98: 877-879. [Abstract/Free Full Text]
  31. Ozaki, K., R. Spolski, C. G. Feng, C. F. Qi, J. Cheng, A. Sher, H. C. Morse, 3rd, C. Liu, P. L. Schwartzberg, W. J. Leonard. 2002. A critical role for IL-21 in regulating immunoglobulin production. Science 298: 1630-1634. [Abstract/Free Full Text]
  32. Parrish-Novak, J., S. R. Dillon, A. Nelson, A. Hammond, C. Sprecher, J. A. Gross, J. Johnston, K. Madden, W. Xu, J. West, et al 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63. [Medline]
  33. King, C., A. Ilic, K. Koelsch, N. Sarvetnick. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117: 265-277. [Medline]
  34. Fehniger, T. A., M. A. Cooper, G. J. Nuovo, M. Cella, F. Facchetti, M. Colonna, M. A. Caligiuri. 2003. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101: 3052-3057. [Abstract/Free Full Text]
  35. Ferlazzo, G., M. Pack, D. Thomas, C. Paludan, D. Schmid, T. Strowig, G. Bougras, W. A. Muller, L. Moretta, C. Munz. 2004. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. USA 101: 16606-16611. [Abstract/Free Full Text]
  36. Cooper, M. A., T. A. Fehniger, A. Fuchs, M. Colonna, M. A. Caligiuri. 2004. NK cell and DC interactions. Trends Immunol. 25: 47-52. [Medline]
  37. Moretta, A.. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2: 957-964. [Medline]
  38. Assarsson, E., T. Kambayashi, J. D. Schatzle, S. O. Cramer, A. von Bonin, P. E. Jensen, H. G. Ljunggren, B. J. Chambers. 2004. NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J. Immunol. 173: 174-180. [Abstract/Free Full Text]
  39. Zingoni, A., T. Sornasse, B. G. Cocks, Y. Tanaka, A. Santoni, L. L. Lanier. 2004. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J. Immunol. 173: 3716-3724. [Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, R.
Right arrow Articles by Shi, F.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, R.
Right arrow Articles by Shi, F.-D.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
Medline Plus Health Information
*Autoimmune Diseases

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS